ReviewFrontiers in nutrition2025
Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Metabolic syndrome confers a higher risk of oral cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- A bibliometric analysis of the Mediterranean diet in metabolic syndrome (2015-2025).Frontiers in nutrition · 2026Pooled it
- The effect of DASH diet on components of metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.Frontiers in nutrition · 2026Pooled it
- Assessing the Diagnostic Performance of Triglyceride-Glucose-Based Indices for Early Detection of Metabolic Syndrome in Paediatric Down Syndrome.Journal of intellectual disability research : JIDR · 2026Article
- Leg fat-to-total fat ratio improves waist-to-height ratio for discriminating metabolic syndrome: a nationwide cross-sectional study.Journal of endocrinological investigation · 2026Article
- Natural Ellagitannins as Potential Therapeutic Agents for Metabolic Syndrome-Related Disorders.Foods (Basel, Switzerland) · 2026Review
- Differential Expression of Human and Bacterial Proteins Reveals Microbiome-Host Crosstalk in Metabolic Disorders.Proteomics. Clinical applications · 2026Article
- Review
- Mechanistic Insights into Houttuynia cordata Thunb. as a Potential Therapeutic Strategy Targeting Metabolic Disorders in Preclinical Models.Current nutrition reports · 2026Review
- Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.JAMA oncology · 2026Article
- Association Between Vitamin D Status, Metabolic Syndrome, and Menopausal Type: A Comparative Observational Study in Women with Early and Physiological Menopause.Biomedicines · 2026Article
- Ethnomedicinal Uses, Phytochemistry and Bioactivities of Halophytes and Salt-Tolerant Plants with Potential Against Metabolic Syndrome: A Comprehensive Review.Marine drugs · 2026Review
- The Gut-Brain Axis in Metabolic Syndrome: Emerging Mechanisms and Perspectives in Personalized Medicine.International journal of molecular sciences · 2026Review
- Special Issue "Neuroinflammation and Neurodegeneration: Molecular Mechanism and Novel Therapy".International journal of molecular sciences · 2026Article
- Association between perceived stress and metabolic parameters: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2026Review
- Predictors of metabolic syndrome among type II diabetic patients visiting public hospitals in Sidama Region, Ethiopia: unmatched case control study.BMC cardiovascular disorders · 2026Article
- Visceral Adiposity and Markers of Relative Sarcopenia in Young Adults with Normal Weight Obesity: Gender Differences.Healthcare (Basel, Switzerland) · 2026Article
- Multistate markov model analysis of metabolic syndrome progression in a community-based longitudinal cohort study.Diabetology & metabolic syndrome · 2026Article
- Review
- Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a complex condition marked by central obesity, dyslipidemia, hypertension, insulin resistance, oxidative stress, and chronic inflammation. These risk factors significantly raise the risk of cardiovascular disease (CVD) through various mechanisms, leading to a public health challenge. MetS contributes to CVD through cardiometabolic derangements such as endothelial dysfunction, atherosclerosis, oxidative stress, and inflammation. Dyslipidemia, especially elevated triglycerides and reduced high-density lipo-protein (HDL) cholesterol is central to atherosclerosis. Additionally, hypertension and insulin resistance damage blood vessels, a process exacerbated by chronic inflammation and oxidative stress. Thus, managing MetS and its components through lifestyle changes like weight control, dietary improvements, exercise, and smoking cessation is essential for reducing CVD risk. Medications targeting specific risk factors, such as blood sugar, cholesterol, and blood pressure, may also be required. Raising awareness and early screening are crucial to countering MetS's impact on public health. This review provides a comprehensive overview of the mechanisms by which MetS contributes to CVD and the intricate interplay of factors and molecular pathways linking MetS to CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.